Publications & Posters Publications & Posters - 2022 SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response Continue Reading
Publications & Posters Publications & Posters - 2022 SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies Continue Reading
Publications & Posters Publications & Posters - 2022 Journal for ImmunoTherapy of Cancer: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. Continue Reading